From cutting-edge advances in information technology, energy-efficiency and lifesaving medical devices and medicines, California’s manufacturers are global leaders in innovation.
At the forefront of innovation is research and development (R&D). The manufacturing industry in California spent $81.7 billion on R&D in 2012—ranking it first nationally. From years of R&D stems manufacturers’ trade secrets and proprietary intellectual property (IP), which is the lifeblood of the industry and the key to creating new consumer goods and generating more effective and efficient technologies. Therefore, there is nothing more critical to California’s manufacturers than the guarantee that their IP will be protected.
Unfortunately, recently introduced legislation would require manufacturers in the pharmaceutical, biopharmaceutical and biotech-related industries to disclose proprietary operational information and data. The bill’s sponsors likely had the best intentions in mind, as it is important that we work to reduce our nation’s health care costs and access. However, this legislation would have the opposite effect. Mandating manufacturers of medical devices and medicines to turn over sensitive data, such as the cost of R&D, would have no impact on controlling costs, but would severely hamper their ability to compete.
The legislation singles out one industry, but devalues the work of all innovators and would send a chilling effect across the manufacturing industry. R&D is risky and expensive, but the rewards are tremendous and should not be desensitized. In California alone, total output from manufacturing was $255.53 billion in 2014, employing 1,271,000 Californians. Manufacturers are the lead drivers of innovation, creating economic growth and jobs. Legislators in California must understand how critical strong IP protections are to protecting the industry and the state’s economy.